Transgene Announces that its Phase 2 study of Pexa-Vec in Second-line Advanced Liver Cancer did not Meet its Primary Endpoint
September 03 2013 - 10:45AM
Business Wire
- Conducting additional analyses of
data, continuing to advance clinical trials in other
cancers
- Announcing decision on Phase 3
development in HCC in Q4
Tong Ren Tang Technologies (TG:TNG)
Historical Stock Chart
From Jan 2025 to Feb 2025
Tong Ren Tang Technologies (TG:TNG)
Historical Stock Chart
From Feb 2024 to Feb 2025
Real-Time news about Tong Ren Tang Technologies Co (Tradegate (DE)): 0 recent articles
More Transgene SA News Articles
